Sagimet Biosciences, Inc. Class A (SGMT) Price & Analysis

Compare

1,569 Followers

SGMT Stock Chart & Stats

$7.36

-$0.58(-10.41%)

At close: Jan 08 4:00 PM EST

$7.36

-$0.58(-10.41%)

Day’s Range― - ―

52-Week Range$1.73 - $11.41

Previous CloseN/A

Volume1.06M

Average Volume (3M)520.77K

Market Cap

$228.17M

Enterprise Value$120.07M

Total Cash (Recent Filing)$125.41M

Total Debt (Recent Filing)$152.00K

Price to Earnings (P/E)―

Beta3.22

Next Earnings

Nov 12, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding31,001,108

10 Day Avg. Volume599,534

30 Day Avg. Volume520,775

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.53

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.85

Forecast

1Y Price Target

$27.00

Price Target Upside266.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentThe combination therapy of denifanstat and resmetirom is advancing into a Phase I PK study, indicating progress in clinical development efforts.

Financial StabilitySagimet Biosciences has enough cash, $135 million, to support operations through the completion of Phase 1 trials, indicating financial stability.

Market DemandThere is a high demand for effective, non-antibiotic oral treatments in moderate to severe acne, which denifanstat can potentially fulfill.

Bears Say

Financial PerformanceThe company reported a net loss of $10.4 million in the second quarter, which may be a concern for investors.

Investor ConcernsThe net loss reported in the second quarter raises concerns about the company's financial performance among investors.

Sagimet Biosciences, Inc. Class A News

Sagimet Biosciences to present Phase 2b FASCINATE-2 study results

Sagimet Biosciences (SGMT) announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement...

13d ago

SGMT

Sagimet announces dosing in Phase 1 PK trial of denifanstat with resmetirom

Sagimet Biosciences (SGMT) announced that the Company has dosed the first participants in a Phase 1 pharmacokinetic trial...

19d ago

SGMT

Buy Rating for Sagimet Biosciences: Promising Clinical Developments and Synergistic Therapy Potential

Analyst Edward Nash from Canaccord Genuity reiterated a Buy rating on Sagimet Biosciences, Inc. Class A and keeping...

18d ago

SGMT

Sagimet Biosciences reports data from Phase 3 trial on denifanstat

Sagimet Biosciences (SGMT) reported that data from a Phase 3 clinical trial for the treatment of moderate to...

1M ago

SGMT

Sagimet Biosciences announces presentations at MASH Drug Development Summit

Sagimet Biosciences (SGMT) announced that the Company will give two oral presentations and participate in a drug development...

1M ago

SGMT

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A. The...

2M ago

SGMT

Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMT stock, giving a Buy rating on...

2M ago

SGMT

Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price...

2M ago

SGMT

Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating

Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

2M ago

SGMT

Sagimet Biosciences Reports Progress in Acne and MASH Trials

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q2 earnings. Here is a breakdown of...

2M ago

SGMT

Sagimet Biosciences Enters New Sales Agreement with Leerink

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has issued an update. Sagimet Biosciences Inc. announced on August...

2M ago

SGMT

Sagimet Biosciences, Inc. Class A: Promising Combination Therapy for MASH Drives Buy Rating

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Sagimet Biosciences, Inc. Class A and keeping...

2M ago

SGMT

Sagimet Biosciences Reports Q2 Results and Clinical Progress

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has shared an announcement. On August 13, 2025, Sagimet Biosciences...

2M ago

SGMT

Sagimet Biosciences announces anticipated upcoming milestones

Sagimet plans to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination...

2M ago

SGMT

SGMT FAQ

What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?

Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.

What is Sagimet Biosciences, Inc. Class A’s market cap?

Sagimet Biosciences, Inc. Class A’s market cap is $228.17M.

When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?

Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Nov 12, 2025 which is in 23 days.

How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?

Sagimet Biosciences, Inc. Class A released its earnings results on Aug 13, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.508 by $0.188.

Is Sagimet Biosciences, Inc. Class A overvalued?

According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sagimet Biosciences, Inc. Class A pay dividends?

Sagimet Biosciences, Inc. Class A does not currently pay dividends.

What is Sagimet Biosciences, Inc. Class A’s EPS estimate?

Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.39.

How many shares outstanding does Sagimet Biosciences, Inc. Class A have?

Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.

What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?

Sagimet Biosciences, Inc. Class A reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.508. Following the earnings report the stock price went up 0.314%.

Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?

Currently, no hedge funds are holding shares in SGMT

Sagimet Biosciences, Inc. Class A Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.89%

Trailing 12-Months

Asset Growth

-27.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sagimet Biosciences, Inc. Class A

Sagimet Biosciences, Inc. Class A (SGMT) is a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics targeting key metabolic pathways to treat diseases with unmet medical needs. The company focuses primarily on the development of innovative drugs for the treatment of liver diseases, cancer, and other metabolic disorders, leveraging its expertise in fatty acid synthase (FASN) inhibition.

Sagimet Biosciences, Inc. Class A (SGMT) Earnings & Revenues

Historic Earnings Reports

SGMT Stock 12 Month Forecast

Average Price Target

$27.00

▲(266.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","30":"$30","8.25":"$8.25","15.5":"$15.5","22.75":"$22.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.25,15.5,22.75,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,8.673846153846155,10.367692307692309,12.061538461538461,13.755384615384616,15.44923076923077,17.143076923076922,18.836923076923078,20.53076923076923,22.224615384615383,23.91846153846154,25.61230769230769,27.306153846153844,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,8.52,10.06,11.600000000000001,13.14,14.68,16.22,17.76,19.3,20.84,22.380000000000003,23.92,25.46,{"y":27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.98,8.366153846153846,9.752307692307692,11.138461538461538,12.524615384615384,13.91076923076923,15.296923076923077,16.683076923076925,18.06923076923077,19.455384615384617,20.841538461538462,22.22769230769231,23.613846153846154,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >